E. Rouits

发表

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

E. Gamelin, M. Boisdron-Celle, A. Morel, 2008, British Journal of Cancer.

Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity

E. Gamelin, M. Boisdron-Celle, A. Morel, 2004, Clinical Cancer Research.

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

David C. Smith, H. Hurwitz, H. Pitot, 2015, Cancer Chemotherapy and Pharmacology.

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.

David C. Smith, H. Hurwitz, H. Pitot, 2014 .

Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol in routine practice. For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake.

E. Gamelin, M. Boisdron-Celle, A. Morel, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Tumor Distribution by Quantitative Mass Spectrometry Imaging of the Inhibitor of Apoptosis Protein Antagonist Xevinapant in Patients with Resectable Squamous Cell Carcinoma of the Head and Neck (EudraCT Number: 2014-004655-31).

J. Bosq, A. Haouala, J. Stauber, 2022, Analytical chemistry.

Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.

S. Irie, A. Stockis, K. Matsuguma, 2014, Drug metabolism and pharmacokinetics.

Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

F. Brichory, P. Rochaix, S. Temam, 2021, Clinical and translational science.

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

N. Magné, B. Chauffert, J. Bourhis, 2020, The Lancet. Oncology.

Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study

I. Ray-Coquard, P. Fumoleau, M. Sablin, 2015 .

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

R. Larson, J. Dipersio, M. Tallman, 2015, Clinical lymphoma, myeloma & leukemia.

Non-linear pharmacokinetics of irinotecan in mice

S. Guichard, P. Canal, E. Chatelut, 2002, Anti-cancer drugs.

SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY

H. Nauwelaerts, M. André, M. Trněný, 2021, Hematological Oncology.

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

J. Soria, P. Fumoleau, A. Hollebecque, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.

K. Gelmon, M. Sawyer, P. Ellis, 2019, Journal of Clinical Oncology.

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

R. Larson, J. Dipersio, M. Tallman, 2016 .

Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake

E. Gamelin, M. Boisdron-Celle, A. Morel, 2003 .

Pharmacokinetics of levetiracetam XR 500mg tablets

A. Stockis, I. Burton, E. Rouits, 2009, Epilepsy Research.